Phase IIa study of pharmacokinetics and pharmacodynamics, to confirm the inhibitory effect of temsirolimus on the mTOR pathway in endometrial cancer.

Trial Profile

Phase IIa study of pharmacokinetics and pharmacodynamics, to confirm the inhibitory effect of temsirolimus on the mTOR pathway in endometrial cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Endometrial cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms POEM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Apr 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 24 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top